IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 6, 2009, Pages 408-416

  Martínez Cordero, Erasmo ^a,b   Trejo, Alejandro Padilla ^b   Aguilar León, Diana E ^c  

^a Laboratory of Research in Autoimmunity   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antinuclear antibodies; Autoantibodies; Connective tissue disease; Immunoglobulins; Recombinant protein; Scleroderma

Indexed keywords

COMPLEMENTARY DNA; DNA TOPOISOMERASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; MOLECULAR CLONING; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTIGENS; BLOTTING, WESTERN; DNA TOPOISOMERASES, TYPE I; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SCLERODERMA, SYSTEMIC;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 73249121668     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20342     Document Type: Article

References (55)

1. Medsger Jr TA. Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis, and calcinosis. In: McCarty DJ, editor. Arthritis and Allied Conditions. Philadelphia: Lea & Febiger. 1989. p 1118-1165.
2. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-10522.
3. Steen VD, Powell DL, Medsger Jr TA. Clinical correlation and prognosis based on serum autoantibodies in patients with systemic sclerosis. Intern Rev Immunol 1995;12:145-157.
4. Weiner ES, Earshaw WC, Senecal JL, et al. Clinical association of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988;31:378-385.
5. Rothfield N, Kurtzman S, Vazques-Abad D, et al. Association of antitopoisomerase l with cancer. Arthritis Rheum 1992;35:724.
6. Steen VD, Powell DL, Medsger Jr TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
7. D'Arpa P, White-Cooper H, Cleveland DW, et al. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arthritis Rheum 1990;33:1501-1511.
8. Verheijen R, Van Den Hoogen F, Beijer R, et al. A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis. Clin Exp Immunol 1990;80:38-43.
9. Jarzabek-Chorzelska M, Blaszczyk M, Kolacinska-Strasz Z, et al. Are ACA and Scl-70 antibodies mutually exclusive? Br J Dermatol 1990;122:201-208.
10. Verheinjen R, De Jong BAW, Van Venrooij WJ. A recombinant topoisomerase I ELISA: Screening for IgG, IgM and IgA antitopo-I autoantibodies in human sera. Clin Exp Immunol 1992;89:456-560.
11. Cram DS, Fisicaro N, McNeilage LJ, et al. Antibody specificities of Thai and Australian scleroderma sera with topoisomerase l recombinant fusion proteins. J Immunol 1993;151:6872-6881.
12. Piccinini G, Cardellini E, Reimer G, et al. An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients. Mol Immunol 1991;28:333-339.
13. Seelig HP, Schröter H, Ehrfeld H, et al. Autoantibodies against topoisomerase-I detected with natural enzyme and overlapping recombinant peptides. J Immunol Methods 1993;165:241-253.
14. Kato T, Yamamoto K, Takeuchi H, et al. Identification of a universal B cell epitope on DNA topoisomerase I an autoantigen associated with scleroderma. Arthritis Rheum 1993;36:1580-1587.
15. Kuwana M, Kaburaki J, Okano Y, et al. The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma). J Clin Invest 1993;92:1296-1301.
16. Kuwana M, Medsger Jr TA, Wright TM. Detection of anti-DNA topoisomerase I antibody by an enzyme linked immunosorbent assay using overlapping recombinant polypeptides. Clin Immunol Immunopathol 1995;76:266-278.
17. Kumana M, Medsger Jr TA, Wright TM. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest 1995;96:586-596.
18. Whyte J, Earnshaw WC, Champoux JJ, et al. Detection of antitopoisomerase I antibody using a full length human topoisomerase I recombinant protein purified from a baculo virus expression system. Clin Exp Immunol 1995;100:214-218.
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association diagnostic and Therapeutic Criteria Committee: Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
20. Clements P, Lachenbrush P, Seibold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-1285.
21. Martínez-Cordero E, Burgos-Vargas R, Herrera-Esparza R, et al. Perfil de anticuerpos antinucleares en la esclerosis sistémica progresiva. Estudio multicéntrico. Rev Invest Clín Méx 1983;35:273-277.
22. Burgos-Vargas R, Martínez-Cordero E, Reyes PA, et al. Antibody pattern and other criteria for diagnosis and classification in progressive systemic sclerosis. J Rheumatol 1988;15:153-154.
23. Martínez-Cordero E. Antinuclear antibodies associated with pulmonary involvement in systemic sclerosis. Chest 1989;96:960-961.
24. Martínez-Cordero E, López-Zepeda J, Martínez-Miranda E, et al. Esclerosis generalizada (esclerodermia) en pacientes pediátricos. Bol Méd Hosp Infant Méx 1989;46:641-648.
25. Martínez-Cordero E. Alteraciones pulmonares y esofágicas en niños con esclerosis generalizada (esclerodermia). Arch Bronconeumol 1990;26:77-78.
26. Martínez-Cordero E, Fonseca MC, Aguilar León DE, et al. Juvenile systemic sclerosis. J Rheumatol 1993;20:905-907.
27. Alonso-Ruiz A, Zea-Mendoza C, Salazar-Vallinas JM, et al. Toxic oil syndrome. A syndrome with features overlapping those of various forms of scleroderma. Sem Arthritis Rheum 1986;15:200-212.
28. Liu LF, Miller KG. Eukaryotic DNA topoisomerases: Two forms of type l DNA topoisomerase from HeLa cell nuclei. Proc Natl Acad Sci USA 1981;78:3487-3491.
29. Goto T, Laipis P, Wang JC. The purification and characterization of DNA polymerases I and II of the yeast Saccharomyces cerevisiae. J Biol Chem 1984;259:10422-10429.
30. Schmitt B, Buhre U, Vosberg HP. Characterization of size variants of type I DNA topoisomerase isolated from calf thymus. Eur J Biochem 1984;144:127-134.
31. Hildebrandt S, Weiner E, Senecal JL, et al. Autoantibodies to topoisomerase-I (Scl-70): Analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1990;57:399-410.
32. Leon DEA, Tellez Araiza M, Arellano García J, et al. Interference effect by rheumatoid factor activity in the detection of antiavian antibodies in pigeon breeder's disease. Clin Exp Med 2002;2:59-67.
33. Gussin HAE, Ignat GP, Varga J, et al. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:376-383.
34. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
35. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
36. Catoggio LJ, Bernstein RM, Black CM, et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983;42:23-27.
37. Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis: anticentromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-625.
38. Van Venrooij WJ, Stapel SO, Houbwn H, et al. Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest 1985;75:1053-1060.
39. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, et al. Scl-70 antibody - a specific marker of systemic sclerosis. Br J Dermatol 1986;115:393-401.
40. Shero JH, Bordwell B, Rothfield NF, et al. Antibodies to topoisomerase l in sera from patients with scleroderma. J Rheumatol 1987;14:138-140.
41. Gleisler C, Hoier-Madsen M. An enzyme-linked immunosorbent assay for autoantibodies against the nuclear protein Scl-70. J Immunol Methods 1985;80:211-219.
42. Maul GG, French BT, Van Venrooij WJ, et al. Topoisomerase l identified by scleroderma 70 antisera: Enrichment of topoisomerase l at the centromere in mouse mitotic cell before anaphase. Proc Natl Acad Sci USA 1986;83:5145-5149.
43. Kumar V, Kowalewski C, Koelle M, et al. Scl-70 antigen stability and its effect on antibody detection in scleroderma. J Rheumatol 1988;15:1499-1502.
44. Tsay GJ, Fann R-H, Huang J. Specificity of anti-Scl-70 antibodies in scleroderma: Increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990;17:1314-1319.
45. Bizzaro N, Tonutti E, Villalta D, et al. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl-70) autoantibodies: Results of a multicenter study. Clin Chem 2000;41:1681-1685.
46. Hidebrandt S, Weiner E, Senécal J-L, et al. The lgG, lgM, and lgA isotypes of anti-topoisomerase I and anticentromere autoantibodies. Arthritis Rheum 1990;33:724-727.
47. Kuwana M, Kaburaki J, Arnett FC, et al. Influence of ethnic background on clinical and serological features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-474.
48. Kuwana M, Kaburaki J, Mimori T, et al. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074-1084.
49. Pudifin DJ, Dinnematin H, Duursma J. Antinuclear antibodies in systemic sclerosis. Clinical and ethnic associations. S Afr Med J 1991;80:438-440.
50. Reveille JD, Durban E, Goldstein R, et al. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35:216-218.
51. Hildebrandt S, Jäckh G, Weber S, et al. A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int 1993;12:231-234.
52. Vázquez-Abad D, Russell CA, Cusick SM, et al. Longitudinal study of anticentromere and anti-topoisomerase-I isotypes. Clin Immunol Immunopathol 1995;74:257-270.
53. Sato S, Hamaguchi Y, Hasegawa M, et al. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology 2001;40:1135-1140.
54. Ho TK, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003;5:80-93.
55. Weiner ES, Hildebrandt S, Senécal JL, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991;34:68-77.